Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.
about
Direct regulation of TWIST by HIF-1alpha promotes metastasisTricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxinsPrognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-AnalysisThe potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivoAnti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrenceRecent developments in targeting carbonic anhydrase IX for cancer therapeuticsPrognostic value of HIFs expression in head and neck cancer: a systematic reviewHIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical CancerNormal tissue radioprotection by amifostine via Warburg-type effectsThe impact of O2 availability on human cancerHypoxia promotes colon cancer dissemination through up-regulation of cell migration-inducing protein (CEMIP)Correlation of expression of hypoxia-related proteins with prognosis in oral squamous cell carcinoma patients.Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells.Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical studyMolecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts.Molecular mechanisms of hypoxia in cancer.Clinical biomarkers for hypoxia targetingHIF-2alpha-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia.Intermittent hypoxia effect on osteoclastogenesis stimulated by neuroblastoma cells.Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion.Feasibility of dose painting using volumetric modulated arc optimization and delivery.Expression of hypoxic marker CA IX is regulated by site-specific DNA methylation and is associated with the histology of gastric cancer.PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells.Hypoxia-inducible factor in thyroid carcinomaAntiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical responseAcquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours.Luteolin inhibits Cr(VI)-induced malignant cell transformation of human lung epithelial cells by targeting ROS mediated multiple cell signaling pathways.Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.Prognostic impacts of hypoxic markers in soft tissue sarcomaDesign and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathwayEffects of the aqueous extract of a Tibetan herb, Rhodiola algida var. tangutica on proliferation and HIF-1α, HIF-2α expression in MCF-7 cells under hypoxic condition in vitroMetabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cellsHypoxia in head and neck cancer.New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting.Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapyHypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo.Immunohistochemical detection of changes in tumor hypoxiaMolecular signatures in urologic tumors.Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
P2860
Q24316939-A7029C7D-8244-4D85-92A9-3124BF3FA7E4Q24651122-6E1E20C6-6766-4251-9F0C-8A8D4845ED2BQ26749393-C8E25061-AB83-4BA1-8CEC-ACB489A1B2ECQ26827175-442AEA21-4CB4-48A4-9D6A-454F862E3BC7Q27010314-52855511-4EC7-46DD-A478-165F78B1525BQ27013023-02E51FD2-4B09-47F1-B6A2-88B2A3FB3F03Q27692688-FBFF39F9-2EBD-4AFD-A50A-57B6773348C9Q27851557-DCC3BB76-E358-4DA8-98F9-8ABC2EE4647FQ28250852-392AC171-6173-403D-B365-561C9175FAC1Q28830846-519041EE-CBFA-4224-822F-04E92D602682Q29619884-B8BA1100-DDDF-4516-9B94-A67EEB2B492DQ30279300-E21E1A4B-74DE-45C1-B7B1-6C59EBAA7ED6Q30318094-90A355AE-4FC0-4486-B430-2BBB9F19C8C1Q30838633-F7B3FB91-B702-4BD6-8087-9DE0F431A5D8Q33384970-80B84245-14F6-4572-8274-A41CDD1AFC05Q33594289-21F20834-69A4-4CB8-B559-A41A49BBCCE8Q33705108-2D0C97D7-78CB-4E3C-A356-F2DCCCC0E96EQ33714638-DC131CDD-7547-476B-A37E-864F1E51AAADQ33947789-5194F1D6-633C-4F14-8A48-C28FE8B18ADEQ34078699-B6E483FC-555D-4033-93CE-D09CC4EBC2B1Q34101627-F433A791-6CF5-456D-9DBF-0EC0615A1B03Q34662439-190C9489-C7D5-4D28-8A19-20595C025B21Q34756174-C24F9061-67E2-47CC-AF32-CCBFF2E050BBQ34778484-0B4B5D51-1C54-4CB8-BC90-972F6413322AQ35099457-62ED4780-0A41-4011-B040-7E92B64A4E54Q35109141-985093F7-921B-49E6-A410-55023051C6D8Q35275024-0D062913-1B80-4166-9A10-C7B74D6673C7Q35610268-5DA0AE56-72A3-4D91-B35E-CB86E63A728EQ35673572-D47E5B48-DCD0-4981-ADE0-CBE31F68F22AQ35789146-122852D4-3956-4C80-9901-4A5B3DCB93E2Q35799673-39FC7841-C624-4830-BB77-C6865D81443EQ35954293-1954AD78-4E60-4EE0-8235-3F0DEDB960DEQ36304128-5E3F02A2-9141-45E7-B6C2-BBD25C338D93Q36541242-93DFB00D-63C2-43AD-9530-B4A1F5442182Q36807138-BAE79D32-6328-4478-827B-DF9D04491F40Q36952188-B0DB0B62-C37C-4FFF-A06E-C2ABC4F75BD3Q37104879-14233274-1817-4C80-858E-EEB0A74958A8Q37188441-B02E4B57-F57C-4098-BF64-59CB10B9A96DQ37225156-1A7ABBBA-7731-44F7-90EA-E11415B852A4Q37228059-33BC2851-BB4D-494D-97B6-A71074D8B778
P2860
Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Endogenous markers of two sepa ...... in the CHART randomized trial.
@en
Endogenous markers of two separate hypoxia response pathways
@nl
type
label
Endogenous markers of two sepa ...... in the CHART randomized trial.
@en
Endogenous markers of two separate hypoxia response pathways
@nl
prefLabel
Endogenous markers of two sepa ...... in the CHART randomized trial.
@en
Endogenous markers of two separate hypoxia response pathways
@nl
P2093
P50
P921
P356
P1476
Endogenous markers of two sepa ...... in the CHART randomized trial
@en
P2093
Alexandra Giatromanolaki
Efthimios Sivridis
Frances M Daley
Michael I Koukourakis
Michele I Saunders
Stanley Dische
P304
P356
10.1200/JCO.2005.02.7474
P407
P577
2006-01-17T00:00:00Z